1 min read

Opportunities for Treg cell therapy for the treatment of human disease

On this page

Share

Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population can develop in the thymus and in the peripheral tissues of the immune system through the expression of an epigenetically stabilized transcription factor, FOXP3. Treg cells mediate their tolerogenic effects using multiple modes of action, including the production of inhibitory cytokines, cytokine starvation of T effector (e.g., IL-2), Teff suppression by metabolic disruption, and modulation of antigen-presenting cell maturation or function.

Related Articles

Explore posts connected to this topic

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding...

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and